banner


About Gland Pharma

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer [HK1] of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the pharmaceutical research and development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We have a professional management team and one of our Promoters, Shanghai Fosun Pharma, is a global pharmaceutical major.

Injectable focused company

We are present in sterile injectables, oncology and ophthalmic segments, and focus on complex injectables including NCE-1s, First-to-File products and 505(b)(2) filings. Our products are currently delivered via liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops; and efforts are underway to augment additional manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products. We are also in the process of including new delivery systems such as pens and cartridges into our product portfolio.

Our ethos at work is to consistently focus on meeting diverse injectable needs with high-quality products at attractive price points. On this strong plinth of looking ahead, we have successfully and repeatedly harnessed our R&D expertise in synthesizing complex molecules to produce complex injectables. Enabling us to develop niche products for diverse markets worldwide.

MISSION

To be a global injectables player, providing value-added total solutions.

VALUES

To foster a work culture that combines work skills with a keen and empathetic understanding of the societies we deal with.

  • Teamwork
  • Innovative Spirit
  • Customer Responsiveness
  • Safety
  • Integrity and Transparency
  • Social Responsibility
QUALITY POLICY

Instil Ethics, Excellence and Efficacy in every product and strive to be a global leader. We accomplish this through:

  • Teamwork
  • Commitment to Current Good Manufacturing practices
  • Continual Improvement of QMS
  • Continuing education and Training

We firmly believe that learning is an on-going process. Our aim and efforts have always been to attract the best talent and provide a supportive workplace conducive to all-round productivity. Innovative and creative thinking is encouraged, and employees are given ample opportunity to express their ideas.

As an equal-opportunity employer, we encourage constructive participation in all aspects. Our policies and procedures ensure fairness and impartiality. We support a culture of collaboration and meritocracy. This has helped build teams with like-minded goals and aspirations. We develop and implement wide-ranging training programs to bring about measurable change in knowledge, skills, attitude and social behaviour of our employees.

To support that relentless hunt for innovation and excellence in our staff, we implement training programs to enhance knowledge, skills, attitude and social behavior of our employees.

Please note that Gland Pharma has deployed a merit-based employee selection practice. We do not charge/accept any amount or security deposit from job seekers during the selection process or while inviting candidates for an interview. Some fraudsters are using the name of Gland Pharma and its employees to solicit job applications and require the job seekers/applicants to pay processing fees or deposit amounts, by sending false e-mails or by making fraudulent telephone calls.

We request you to not respond to these calls/emails. Please also do not share original/scan/photocopies of your identity proof documents, residential proof documents and educational certificates with these fraudsters, since there is a possibility of misuse of such documents by them.

We shall not accept any liability towards the representation made in any fraudulent communication or its consequences, and such fraudulent communication shall not be treated as any kind of offer or representation by Gland Pharma. Please do alert your family and friends so that no one else falls for this fraud offer. Please send your correspondence pertaining to the fraudulent recruitment at gland@glandpharma.com

pvn raju, founder of gland pharma
PVN Raju

PVN Raju is a Graduate in Chemistry from the Presidency College of Madras and a Post Graduate from the Indian Institute of Chemists. He received training at Evans Medical in the UK and Pharmacia in Sweden, before starting Gland Chemicals in 1974 and Gland Pharma in 1978.

The visionary technocrat pioneered Heparin technology in India in 1960, and set up the country’s first state-of-the-art Pre-Filled Syringe (PFS) facility for LMWHs in 1998. It was under his guidance that the facility received USFDA acceptance in 2003, another first in India.

His associations include Life Membership of the Indian Pharmaceutical Association (IPA); Parenteral Drug Association (PDA), USA; and International Society for Pharmaceutical Engineering (ISPE).

His honorary recognitions include:

  • Prof Y Nayudamma Memorial Gold Medal (2005)
  • Special Recognition Award by the South Asian Society on Atherosclerosis and Thrombosis (SASAT) (2006)
Dr. Ravi Penmetsa, Director at gland pharma
Dr. Ravi Penmetsa

After obtaining his MBBS degree from Osmania University (India), Dr Ravi specialized in Science of Medicine from East Carolina University School of Medicine (USA). After seven years’ hospital-based practice there, he joined Gland Pharma as its Executive Director in 1992.

Assuming the mantle of the company’s Managing Director in 1999, Dr Ravi spearheaded its rapid, multi-dimensional growth over the next two decades.

Displaying great foresight and vision, he was instrumental in setting up a comprehensive infrastructure for Research & Development (Analytical and Formulations), as well as Contract Manufacture of a wide range of injectable dosage forms in compliance with the stringent regulatory requirements of the company’s business partners from across the world.

In recognition of his deep and extensive knowledge and experience in the pharmaceutical sector, Dr Ravi has been honoured with several institutional memberships and awards.

Srinivas Sadu, Managing Director at gland pharma
Srinivas SaduManaging Director & Chief Executive Officer

Mr. Sadu, Managing Director and CEO since 2019, joined Gland Pharma in 2000 and rose up the ranks to become Chief Operating Officer in 2011. He holds a master's degree in Industrial Pharmacy from Long Island University, New York; MBA from University of Maryland, Baltimore; and postgraduate certification in Finance and Management from London School of Business and Finance. He has over 23 years of experience in business development, manufacturing operations, supply chain management and strategic planning. He has been associated with Gland Pharma Limited for the last 22 years. He joined the Company as the general manager – exports in 2000, and was elevated to the position of senior general manager in 2002, vice president in 2003, director in 2005, and chief operating officer in 2011. He was appointed as the MD and CEO with effect from April 25, 2019. Under his leadership, the Company has consistently witnessed growth, both in terms of revenue and profits, while expanding across all geographies.

KVGK Raju, Chief Technical Officer at gland pharma
KVGK RajuChief Technical Officer

Mr Raju’s association with the company goes back since its inception and he has closely been connected in putting into place quality control norms and practices as envisaged by our founder. With over 38 years’ experience in Quality Assurance, Quality Control and Regulatory Affairs, Mr Raju holds a Master of Science in Organic Chemistry and Post Graduate Diploma in Industrial Microbiology.

Ravi Shekhar Mitra, Chief Financial Officer at gland pharma
Ravi Shekhar MitraChief Financial Officer

Mr Mitra joined Gland Pharma as CFO in 2019. He is a Qualified Chartered Accountant and Company Secretary with Associate Membership of the respective institutes.

He has over 20 years’ experience in leading Financial Management, FP&A, Strategic Planning, Investor Relations in Pharmaceutical and other industries.

  • 2021

    Purchased assets of Vitane Biologics, Hyderabad based biopharmaceutical company

  • 2020

    Listed on Indian stock exchanges, NSE & BSE

  • 2019

    First product filing in China

  • 2018

    Enoxaparin injection approval received for US market

    First ophthalmic product approval received for US market

  • 2017

    Fosun Pharma acquires majority stake

  • 2016

    First USFDA approval for Penems plant in Hyderabad & Sterile Injectable plant at Pashamylaram, Hyderabad

    First USFDA approval for API plant in VSEZ & for API plant in Pharmacity, Visakhapatnam

  • 2014

    Dedicated facility for Penems commissioned at Pashamylaram, Hyderabad

    Manufacturing lines including Ophthalmic Line and Automated Bag Line added at Dundigal facility

    Gland enters Canada with Amiodarone PFS

  • 2013

    Enters Europe with Tirofiban

    Oncology formulations facility at Visakhapatnam receives USFDA acceptance

  • 2012

    Dundigal formulations facility receives UK MHRA and EMEA approvals

  • 2011

    Forays into Australia with Azithromycin Injection.

    Rocuronium, the first product approval in New Zealand

  • 2010

    Introduces Heparin, its flagship product, in the US market

  • 2007

    Enters the US market with Ketorolac PFS

  • 2003

    Dundigal formulations facility receives USFDA acceptance

  • 2002

    Supplies Enoxaparin in Brazil and other semi-regulated markets

  • 2001

    Launches Enoxaparin injectionin India

  • 2000

    Signs its first Contract Manufacturing agreement for regulated markets

    R&D facility set up at Dundigal, Hyderabad

  • 1998

    Flagship manufacturing facility at Dundigal becomes operational

  • 1996

    Becomes the first company to set up a PFS facility in India, in collaboration with Vetter Pharma, Germany

  • 1994

    Becomes a public limited company from a private limited company

  • 1978

    PVN Raju founds Gland Pharma to manufacture and market Heparin injection for the domestic market and provides contract manufacturing services for other pharmaceutical companies

Corporate Philosophy
MISSION

To be a global injectables player, providing value-added total solutions.

VALUES

To foster a work culture that combines work skills with a keen and empathetic understanding of the societies we deal with.

  • Teamwork
  • Innovative Spirit
  • Customer Responsiveness
  • Safety
  • Integrity and Transparency
  • Social Responsibility
QUALITY POLICY

Instil Ethics, Excellence and Efficacy in every product and strive to be a global leader. We accomplish this through:

  • Teamwork
  • Commitment to Current Good Manufacturing practices
  • Continual Improvement of QMS
  • Continuing education and Training
Work Culture

We firmly believe that learning is an on-going process. Our aim and efforts have always been to attract the best talent and provide a supportive workplace conducive to all-round productivity. Innovative and creative thinking is encouraged, and employees are given ample opportunity to express their ideas.

As an equal-opportunity employer, we encourage constructive participation in all aspects. Our policies and procedures ensure fairness and impartiality. We support a culture of collaboration and meritocracy. This has helped build teams with like-minded goals and aspirations. We develop and implement wide-ranging training programs to bring about measurable change in knowledge, skills, attitude and social behaviour of our employees.

To support that relentless hunt for innovation and excellence in our staff, we implement training programs to enhance knowledge, skills, attitude and social behavior of our employees.

Please note that Gland Pharma has deployed a merit-based employee selection practice. We do not charge/accept any amount or security deposit from job seekers during the selection process or while inviting candidates for an interview. Some fraudsters are using the name of Gland Pharma and its employees to solicit job applications and require the job seekers/applicants to pay processing fees or deposit amounts, by sending false e-mails or by making fraudulent telephone calls.

We request you to not respond to these calls/emails. Please also do not share original/scan/photocopies of your identity proof documents, residential proof documents and educational certificates with these fraudsters, since there is a possibility of misuse of such documents by them.

We shall not accept any liability towards the representation made in any fraudulent communication or its consequences, and such fraudulent communication shall not be treated as any kind of offer or representation by Gland Pharma. Please do alert your family and friends so that no one else falls for this fraud offer. Please send your correspondence pertaining to the fraudulent recruitment at gland@glandpharma.com

Founder
pvn raju, founder of gland pharma
PVN Raju

PVN Raju is a Graduate in Chemistry from the Presidency College of Madras and a Post Graduate from the Indian Institute of Chemists. He received training at Evans Medical in the UK and Pharmacia in Sweden, before starting Gland Chemicals in 1974 and Gland Pharma in 1978.

The visionary technocrat pioneered Heparin technology in India in 1960, and set up the country’s first state-of-the-art Pre-Filled Syringe (PFS) facility for LMWHs in 1998. It was under his guidance that the facility received USFDA acceptance in 2003, another first in India.

His associations include Life Membership of the Indian Pharmaceutical Association (IPA); Parenteral Drug Association (PDA), USA; and International Society for Pharmaceutical Engineering (ISPE).

His honorary recognitions include:

  • Prof Y Nayudamma Memorial Gold Medal (2005)
  • Special Recognition Award by the South Asian Society on Atherosclerosis and Thrombosis (SASAT) (2006)
Dr. Ravi Penmetsa, Director at gland pharma
Dr. Ravi Penmetsa

After obtaining his MBBS degree from Osmania University (India), Dr Ravi specialized in Science of Medicine from East Carolina University School of Medicine (USA). After seven years’ hospital-based practice there, he joined Gland Pharma as its Executive Director in 1992.

Assuming the mantle of the company’s Managing Director in 1999, Dr Ravi spearheaded its rapid, multi-dimensional growth over the next two decades.

Displaying great foresight and vision, he was instrumental in setting up a comprehensive infrastructure for Research & Development (Analytical and Formulations), as well as Contract Manufacture of a wide range of injectable dosage forms in compliance with the stringent regulatory requirements of the company’s business partners from across the world.

In recognition of his deep and extensive knowledge and experience in the pharmaceutical sector, Dr Ravi has been honoured with several institutional memberships and awards.

Management Team
Srinivas Sadu, Managing Director at gland pharma
Srinivas SaduManaging Director & Chief Executive Officer

Mr. Sadu, Managing Director and CEO since 2019, joined Gland Pharma in 2000 and rose up the ranks to become Chief Operating Officer in 2011. He holds a master's degree in Industrial Pharmacy from Long Island University, New York; MBA from University of Maryland, Baltimore; and postgraduate certification in Finance and Management from London School of Business and Finance. He has over 23 years of experience in business development, manufacturing operations, supply chain management and strategic planning. He has been associated with Gland Pharma Limited for the last 22 years. He joined the Company as the general manager – exports in 2000, and was elevated to the position of senior general manager in 2002, vice president in 2003, director in 2005, and chief operating officer in 2011. He was appointed as the MD and CEO with effect from April 25, 2019. Under his leadership, the Company has consistently witnessed growth, both in terms of revenue and profits, while expanding across all geographies.

KVGK Raju, Chief Technical Officer at gland pharma
KVGK RajuChief Technical Officer

Mr Raju’s association with the company goes back since its inception and he has closely been connected in putting into place quality control norms and practices as envisaged by our founder. With over 38 years’ experience in Quality Assurance, Quality Control and Regulatory Affairs, Mr Raju holds a Master of Science in Organic Chemistry and Post Graduate Diploma in Industrial Microbiology.

Ravi Shekhar Mitra, Chief Financial Officer at gland pharma
Ravi Shekhar MitraChief Financial Officer

Mr Mitra joined Gland Pharma as CFO in 2019. He is a Qualified Chartered Accountant and Company Secretary with Associate Membership of the respective institutes.

He has over 20 years’ experience in leading Financial Management, FP&A, Strategic Planning, Investor Relations in Pharmaceutical and other industries.

Board of Directors
Milestones
  • 2021

    Purchased assets of Vitane Biologics, Hyderabad based biopharmaceutical company

  • 2020

    Listed on Indian stock exchanges, NSE & BSE

  • 2019

    First product filing in China

  • 2018

    Enoxaparin injection approval received for US market

    First ophthalmic product approval received for US market

  • 2017

    Fosun Pharma acquires majority stake

  • 2016

    First USFDA approval for Penems plant in Hyderabad & Sterile Injectable plant at Pashamylaram, Hyderabad

    First USFDA approval for API plant in VSEZ & for API plant in Pharmacity, Visakhapatnam

  • 2014

    Dedicated facility for Penems commissioned at Pashamylaram, Hyderabad

    Manufacturing lines including Ophthalmic Line and Automated Bag Line added at Dundigal facility

    Gland enters Canada with Amiodarone PFS

  • 2013

    Enters Europe with Tirofiban

    Oncology formulations facility at Visakhapatnam receives USFDA acceptance

  • 2012

    Dundigal formulations facility receives UK MHRA and EMEA approvals

  • 2011

    Forays into Australia with Azithromycin Injection.

    Rocuronium, the first product approval in New Zealand

  • 2010

    Introduces Heparin, its flagship product, in the US market

  • 2007

    Enters the US market with Ketorolac PFS

  • 2003

    Dundigal formulations facility receives USFDA acceptance

  • 2002

    Supplies Enoxaparin in Brazil and other semi-regulated markets

  • 2001

    Launches Enoxaparin injectionin India

  • 2000

    Signs its first Contract Manufacturing agreement for regulated markets

    R&D facility set up at Dundigal, Hyderabad

  • 1998

    Flagship manufacturing facility at Dundigal becomes operational

  • 1996

    Becomes the first company to set up a PFS facility in India, in collaboration with Vetter Pharma, Germany

  • 1994

    Becomes a public limited company from a private limited company

  • 1978

    PVN Raju founds Gland Pharma to manufacture and market Heparin injection for the domestic market and provides contract manufacturing services for other pharmaceutical companies

Awards & Recognition